Clinical Trial Update: Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing maribavir vs valganciclovir for CMV prophylaxis in high-risk kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Maribavir (maribavir)
• Valcyte (valganciclovir)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Transplant Complication, CMV | Phase 4 | Status: COMPLETED